Published in Blood Weekly, December 31st, 2009
"The single-agent activity compares favorably with that demonstrated by the current standard antileukemia agents. Clofarabine has been safely and effectively combined with other agents and will probably become an integral part of induction and/or consolidation regimens in AML," wrote X. Thomas and colleagues.
The researchers concluded: "Current studies are underway to better define the role of clofarabine in younger and elderly patients with AML, and also explore...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.